About This Trial

Bispecific antibody redirecting T-cells to BCMA-expressing myeloma cells.

Primary Endpoints

  • Overall survival
  • Complete response rate

Latest Update

February 2026

Phase 2 showed 63% overall response rate. Registrational Phase 3 fully enrolled ahead of schedule.